Sanjay Popat
Royal Marsden NHS Foundation Trust · Royal Marsden Hospital - Chelsea, London · Royal Marsden Hospital, Chelsea, London, UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sanjay Popat as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07673861 · Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsRoyal Marsden NHS Foundation Trust · recruiting · Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer · principal investigator
- N/ANCT07008742 · Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung CancerRoyal Marsden NHS Foundation Trust · recruiting · Oncogene-addicted Non Small Cell Lung Cancer, Early-stage Operable Non Small Cell Lung Cancer, Non Small Cell Lung Cancer · principal investigator
- Ph2NCT06068153 · AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCETOP IBCSG Partners Foundation · withdrawn · Metastatic Non Small Cell Lung Cancer, KRAS G12C · study chair
- Ph3NCT03762018 · BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural MesotheliomaETOP IBCSG Partners Foundation · completed · Pleural Mesothelioma Malignant Advanced · study chair
- Ph1/Ph2NCT03361319 · Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaRoyal Marsden NHS Foundation Trust · withdrawn · NSCLC, Recurrent, Adenocarcinoma of Lung · principal investigator
- Ph3NCT02991482 · PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaETOP IBCSG Partners Foundation · completed · Pleural Mesothelioma Malignant Advanced · study chair
- Ph2NCT02863055 · Nintedanib as Switch Maintenance Treatment of Pleural Malignant MesotheliomaEuropean Organisation for Research and Treatment of Cancer - EORTC · terminated · Malignant Pleural Mesothelioma · principal investigator
- Ph2NCT02470065 · Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.European Organisation for Research and Treatment of Cancer - EORTC · suspended · Non Small Cell Lung Cancer · principal investigator
- N/ANCT02273271 · Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative ChemoEuropean Organisation for Research and Treatment of Cancer - EORTC · unknown · Non-small Cell Lung Carcinoma · study chair
- N/ANCT01838577 · Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation StudyEuropean Organisation for Research and Treatment of Cancer - EORTC · unknown · EGFR Mutation Positive Non Small Cell Lung Cancer · principal investigator
- Ph2NCT01415011 · Efficacy and Safety Study of Afatinib to Treat Lung Cancer PatientsUniversity College, London · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:52 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- 1,015 citationsRCR 56.5
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2018824 citationsRCR 27.7
- 415 citationsRCR 48.7
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J Med · 2023368 citationsRCR 29.4
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.J Thorac Oncol · 2021359 citationsRCR 18.4
- First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.J Thorac Oncol · 2016292 citationsRCR 9.2
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.J Clin Oncol · 2020263 citationsRCR 10.0
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.J Thorac Oncol · 2020242 citationsRCR 9.6
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2024227 citationsRCR 25.8
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.Lancet Respir Med · 2017159 citationsRCR 4.8